ORIC PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ORIC PHARMACEUTICALS, INC. (ORIC) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 3.69 million shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-03
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 330.80K shares, a 102.10% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 3.36M shares, a 13.90% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 87.60K shares, a 43.19% decline year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 336.50K shares, a 40.09% increase year-over-year.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 3.53M shares, a 20.77% increase from fiscal 2024.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 2.93M shares, a 39.06% increase from fiscal 2023.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 2.10M shares, a 66.78% decline from fiscal 2022.
- ORIC PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 6.34M shares, a 273.83% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 330.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | 3.69M shares 10-Q · filed 2026-08-03 | 3.77M shares derived: sum of 3 quarters · filed 2026-08-03 | 4.11M shares derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | 3.36M shares 10-Q · filed 2026-05-04 | 3.44M shares derived: sum of 2 quarters · filed 2026-05-04 | 3.78M shares derived: sum of 3 quarters · filed 2026-05-04 | 3.94M shares derived: sum of 4 quarters · filed 2026-05-04 |
| 2025-12-31 | 87.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 424.10K shares derived: sum of 2 quarters · filed 2026-02-23 | 587.78K shares derived: sum of 3 quarters · filed 2026-02-23 | 3.53M shares 10-K · filed 2026-02-23 |
| 2025-09-30 | 336.50K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 500.18K shares derived: sum of 2 quarters · filed 2025-11-13 | 3.45M shares 10-Q · filed 2025-11-13 | 3.60M shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 163.68K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 3.11M shares 10-Q · filed 2025-08-12 | 3.26M shares derived: sum of 3 quarters · filed 2025-08-12 | 3.50M shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 2.95M shares 10-Q · filed 2025-05-05 | 3.10M shares derived: sum of 2 quarters · filed 2025-05-05 | 3.34M shares derived: sum of 3 quarters · filed 2025-05-05 | 3.60M shares derived: sum of 4 quarters · filed 2025-05-05 |
| 2024-12-31 | 154.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | 394.40K shares derived: sum of 2 quarters · filed 2025-02-18 | 651.70K shares derived: sum of 3 quarters · filed 2025-02-18 | 2.93M shares 10-K · filed 2025-02-18 |
| 2024-09-30 | 240.20K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | 497.50K shares derived: sum of 2 quarters · filed 2024-11-12 | 2.77M shares 10-Q · filed 2024-11-12 | 2.90M shares derived: sum of 4 quarters · filed 2024-11-12 |
| 2024-06-30 | 257.30K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | 2.53M shares 10-Q · filed 2024-08-12 | 2.66M shares derived: sum of 3 quarters · filed 2024-08-12 | 2.70M shares derived: sum of 4 quarters · filed 2024-08-12 |
| 2024-03-31 | 2.27M shares 10-Q · filed 2024-05-06 | 2.40M shares derived: sum of 2 quarters · filed 2024-05-06 | 2.45M shares derived: sum of 3 quarters · filed 2024-05-06 | 2.58M shares derived: sum of 4 quarters · filed 2024-05-06 |
| 2023-12-31 | 125.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | 172.44K shares derived: sum of 2 quarters · filed 2024-03-11 | 308.12K shares derived: sum of 3 quarters · filed 2024-03-11 | 2.10M shares 10-K · filed 2024-03-11 |
| 2023-09-30 | 47.44K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | 183.12K shares derived: sum of 2 quarters · filed 2023-11-06 | 1.98M shares 10-Q · filed 2023-11-06 | 2.12M shares derived: sum of 4 quarters · filed 2023-11-06 |
| 2023-06-30 | 135.68K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 1.93M shares 10-Q · filed 2023-08-10 | 2.07M shares derived: sum of 3 quarters · filed 2023-08-10 | 6.51M shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 1.80M shares 10-Q · filed 2023-05-08 | 1.94M shares derived: sum of 2 quarters · filed 2023-05-08 | 6.37M shares derived: sum of 3 quarters · filed 2023-05-08 | 6.80M shares derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | 141.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | 4.58M shares derived: sum of 2 quarters · filed 2023-03-16 | 5.00M shares derived: sum of 3 quarters · filed 2023-03-16 | 6.34M shares 10-K · filed 2023-03-16 |
| 2022-09-30 | 4.44M shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 4.86M shares derived: sum of 2 quarters · filed 2022-11-07 | 6.19M shares 10-Q · filed 2022-11-07 | 6.35M shares derived: sum of 4 quarters · filed 2022-11-07 |
| 2022-06-30 | 423.80K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 1.76M shares 10-Q · filed 2022-08-11 | 1.92M shares derived: sum of 3 quarters · filed 2022-08-11 | 2.12M shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 1.33M shares 10-Q · filed 2022-05-09 | 1.49M shares derived: sum of 2 quarters · filed 2022-05-09 | 1.70M shares derived: sum of 3 quarters · filed 2022-05-09 | 1.92M shares derived: sum of 4 quarters · filed 2022-05-09 |
| 2021-12-31 | 159.85K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | 367.30K shares derived: sum of 2 quarters · filed 2022-03-21 | 589.02K shares derived: sum of 3 quarters · filed 2022-03-21 | 1.69M shares 10-K · filed 2022-03-21 |
| 2021-09-30 | 207.45K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | 429.18K shares derived: sum of 2 quarters · filed 2021-11-08 | 1.53M shares 10-Q · filed 2021-11-08 | 1.68M shares derived: sum of 4 quarters · filed 2021-11-08 |
| 2021-06-30 | 221.72K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | 1.33M shares 10-Q · filed 2021-08-10 | 1.48M shares derived: sum of 3 quarters · filed 2021-08-10 | 1.58M shares derived: sum of 4 quarters · filed 2021-08-10 |
| 2021-03-31 | 1.11M shares 10-Q · filed 2021-05-06 | 1.26M shares derived: sum of 2 quarters · filed 2021-05-06 | 1.35M shares derived: sum of 3 quarters · filed 2021-05-06 | |
| 2020-12-31 | 149.90K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-23 | 248.65K shares derived: sum of 2 quarters · filed 2021-03-23 | 1.60M shares 10-K · filed 2021-03-23 | |
| 2020-09-30 | 98.75K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 1.45M shares 10-Q · filed 2020-11-05 | ||
| 2020-06-30 | 1.35M shares 10-Q · filed 2020-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |